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Abstract
The Inside Knowledge: Get the Facts About Gynecologic Cancer campaign raises awareness of 
the five main types of gynecologic cancer: cervical, ovarian, uterine, vaginal, and vulvar. It 
encourages women to pay attention to their bodies and know what is normal for them so they can 
recognize the warning signs of gynecologic cancers and seek medical care. This report provides an 
overview of the development of this national campaign.
Introduction
Each year, about 80,900 women in the United States are diagnosed with and nearly 28,000 
women die from gynecologic cancers.1 A recent report estimates approximately 1 million 
American women who had been diagnosed with a gynecologic cancer were alive as of 
January 1, 2007.2 The five main types of gynecologic cancer are cervical, ovarian, uterine, 
vaginal, and vulvar.
In 2007, the most recent year for which data are available, more than 12,000 women in the 
United States were diagnosed with cervical cancer, and about 4,000 died from it.1 Cervical 
cancer is the easiest female cancer to prevent with regular screening tests and follow-up. It is 
the only gynecologic cancer for which population-based routine screening is recommended. 
That it is not among the top 10 most common or deadliest cancers is largely because of the 
widespread use of the Papanicolaou (Pap) test, which screens for precancers (cell changes 
on the cervix that may become cervical cancer if they are not treated appropriately), and the 
human papillomavirus (HPV) test, which looks for the HPV, the virus that can cause these 
cell changes. The HPV test may be used for screening women aged ≥30 years or at any age 
for women who have unclear Pap test results.
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Ovarian cancer is the deadliest gynecologic malignancy.1 Approximately 20,000 women are 
diagnosed with and about 15,000 women die each year from ovarian cancer.1 Although an 
effective screening test for ovarian cancer does not exist, there have been several advances 
in treatment that have resulted in improved survival from ovarian cancer.3 It is the eighth 
most common cancer among women in the United States and the fifth leading cause of 
cancer deaths.1 Most ovarian cancers are sporadic in nature; however, about 10% of ovarian 
cancer is linked to genetic syndromes.4,5 Women with mutations in the BRCA1 and BRCA2 
genes, and those with Lynch syndrome are at greater risk than the general population for 
ovarian cancer.6
Uterine cancer is the most commonly diagnosed gynecologic cancer (fourth most common 
cancer in women) and is the eighth leading cause of cancer death among American women. 
Every year, about 41,000 women are diagnosed with and nearly 7,500 die from uterine 
cancer.1
Vaginal and vulvar cancers are rare malignancies. In the United States, 1,149 women 
learned they had vaginal cancer, and 376 died from it, and 4,159 women were diagnosed 
with vulvar cancer and 865 died from it in 2007.1 Approximately 40% of vaginal and vulvar 
cancers have been attributed to HPV.7
The Inside Knowledge: Get the Facts About Gynecologic Cancer campaign educates women 
and healthcare providers about the signs, symptoms, risk factors, and prevention strategies 
related to cervical, ovarian, uterine, vaginal, and vulvar cancers. Developed and 
implemented by the Centers for Disease Control and Prevention (CDC), in collaboration 
with the U.S. Department of Health and Human Services’ (HHS) Office on Women’s 
Health, Inside Knowledge supports the Gynecologic Cancer Education and Awareness Act 
of 2005, or Johanna’s Law (www.cdc.gov/cancer/gynecologic/pdf/JohannasLaw.pdf), which 
was signed into law on January 12, 2007. Johanna’s Law authorizes CDC to carry out a 
national campaign to increase women’s and healthcare providers’ awareness and knowledge 
of gynecologic cancers; develop, produce, and maintain a supply of written materials that 
provide information to the public on gynecologic cancers; distribute materials to the public 
on request; develop and place public service announcements (PSAs); and call attention to 
early warning signs and risk factors based on the best available medical information.
Campaign Challenges and Opportunities
A lack of recommended population-based screening for all gynecologic cancers except 
cervical cancer and the wide range and vague nature of symptoms associated with most 
gynecologic cancers present distinct challenges for a national awareness campaign. Another 
significant challenge is that each gynecologic cancer is unique in terms of signs, symptoms, 
risk factors, and prevention strategies.
For cervical cancer, the main messages of the Inside Knowledge campaign include an action 
step that most women can take relatively easily: get screened as recommended. For ovarian 
and other gynecologic cancers, however, key campaign messages center (by necessity) on 
awareness of risk factors and symptom recognition to promote early detection, timely 
treatment, and improved health outcomes. The absence of a clear message promoting 
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screening for ovarian, uterine, vaginal, and vulvar cancers can be frustrating both for women 
who await the development of effective screening strategies and for the medical and public 
health communities that lack evidence-based tools to prevent and detect early disease.8 All 
these factors underscore an important need to educate and communicate with women and 
healthcare providers about gynecologic cancer.
Additional challenges center on what many studies have shown to be common 
misunderstandings and misconceptions about the Pap test and pelvic examination.9–12 
Previous studies have reported that women do not know the purpose of a Pap test and 
believe that it screens for multiple gynecologic cancers, sexually transmitted diseases 
(STDs), and other conditions.8–13 Recent discussions among healthcare providers have also 
questioned the need and purpose of the pelvic examination.14,15
Knowledge among women about symptoms related to gynecologic cancers also is 
lacking.8,16 Symptom recognition is important for both women and their healthcare 
providers, particularly in the absence of recommended screening options, especially in the 
case of ovarian cancer.17 Without understanding what symptoms are associated with ovarian 
cancers, for example, women may discount those that are vague and unspecific, and they 
may go unchecked for some time until symptoms become so persistent or alarming that a 
woman seeks medical attention.18,19 Likewise, educating healthcare providers to recognize 
symptoms that may be potential signs of ovarian cancer may lead to earlier detection at a 
more treatable stage.20,21 Patients with certain gynecologic and gastrointestinal symptoms22 
may benefit substantially from education and awareness or by more active surveillance and 
diagnostic workup.
Although these challenges exist, they have not been insurmountable, as some common 
themes can be extracted and applied. For instance, cervical, vaginal, and vulvar cancers have 
a common thread in their relation to HPV infection, and ovarian and uterine cancers are 
similar in their age of onset (mainly occurring in postmenopausal women) as well as their 
possible genetic connection.6 Therefore, targeted information to these populations of women 
is of great value for multiple gynecologic cancers. Education about the gynecologic organ 
system and functions overall, as well as recommendation of treatment by gynecologic 
oncologists who more often adhere to guidelines-based care, are two examples of cross-
cutting themes that can be applied to every cancer included in the Inside Knowledge 
campaign.
Development of Campaign Messages
During the initial planning stages of the campaign, CDC conducted an extensive literature 
review and environmental scan of existing gynecologic cancer educational materials and 
messages. CDC also developed a logic model for campaign processes, built on formative 
evaluation, pretesting, process evaluation, and outcome evaluation explained in the Health 
Communication Process (National Cancer Institute, 2010) that is endorsed by the HHS. The 
Social Cognitive Theory23 was the primary theoretical foundation guiding both development 
and evaluation activities. However, constructs from a variety of other behavioral and 
communication theories have since been used as needed.
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Concurrently, a few months after Johanna’s Law was enacted, CDC convened a panel of 
gynecologic cancer experts in San Diego, CA, to discuss the state of the science and 
potential education and awareness messages for gynecologic cancers. The panel comprised 
gynecologic oncologists, gynecologists, pediatricians, nurses, other medical practitioners, 
health and behavioral scientists, and representatives of nonprofit and advocacy organizations 
committed to raising awareness of gynecologic cancers.
The general framework and development of Inside Knowledge messages and materials were 
based initially on what was learned in the literature review and during the expert panel 
meeting, where information gaps were identified, and consensus was reached on main 
messages and strategies to raise awareness about gynecologic cancer. Campaign messages 
were further refined based on focus group research conducted across the United States by 
CDC to learn more about women’s gynecologic cancer knowledge, attitudes, beliefs, and 
behaviors. In 2009, CDC conducted 48 focus groups in English and Spanish with a total of 
408 women (262 English speakers and 146 Spanish speakers) aged 40–60 years in New 
York City, Atlanta, Miami, Los Angeles, Houston, Chicago, and Las Vegas. In addition to 
formative research conducted in the focus groups, the groups also served to test creative 
approaches and strategies to ensure that campaign materials delivered intended messages in 
the most effective ways.
The main campaign messages are:
• There are several types of gynecologic cancer.
• When gynecologic cancers are found early, treatment is most effective.
• Pay attention to your body and know what is normal for you. Gynecologic cancers 
have warning signs.
• If you have vaginal bleeding that is unusual for you because of when it occurs or 
how heavy it is, see a doctor right away.
• If you notice any other unexplained signs or symptoms that last for 2 weeks or 
longer, see a doctor.
• Get a Pap test regularly to screen for cervical cancer. (The Pap test does not screen 
for ovarian, uterine, vaginal, or vulvar cancers. Even if you have a Pap test 
regularly, see your doctor if you notice any signs or symptoms that are not normal 
for you.)
• Get the HPV vaccine if you are 11–26 years old.
• If you are diagnosed with a gynecologic cancer, see a gynecologic oncologist, a 
doctor who is trained to treat cancers of the female reproductive system.
Additional Research to Inform the Campaign
In addition to focus groups with consumers as described, Inside Knowledge also conducted 
formative research with healthcare providers in 2011, using a combination of in-person and 
telephone focus groups. There were 24 in-person groups, with 6 groups each in Las Vegas, 
Philadelphia, Atlanta, and Chicago, as well as 6 telephone groups comprising participants 
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from rural, suburban, and urban areas around the country. Of the 30 groups held (in person 
and via telephone), 10 included gynecologists, 10 were with primary care physicians, and 
the remaining 10 were with nurse practitioners. Data analysis from these groups is ongoing, 
with results informing future campaign development.
Campaign messages and strategies are further informed by Porter Novelli’s HealthStyles and 
DocStyles surveys, from which CDC commissioned questions in 2008 and 2009 to gather 
baseline information on women’s and healthcare providers’ knowledge, attitudes, and 
practices related to gynecologic cancer. HealthStyles is a cross-sectional annual survey of 
adults aged ≥18 years that examines beliefs and behaviors about individual health. 
HealthStyles respondents are asked a variety of demographic questions, including 
information on age, race, education, and marital status. In addition, CDC commissioned 
specific questions about gynecologic cancer, including familiarity with and use of screening 
tests, care seeking for potential symptoms of gynecologic cancer, and concern about getting 
gynecologic cancer. A series of analyses have been performed with the data collected. 
Results from the 2008 HealthStyles survey indicate that almost all (about 97%) of the 2,991 
women respondents had heard of the Pap test; however, this proportion was lower in women 
aged 18–34 years and among those who had lower levels of education and income.13 Over 
80% of the respondents knew the Pap test was used to screen for cervical cancer; however, 
substantial percentages of women (35%–45%) erroneously thought the Pap test was also 
used to screen for other gynecologic cancers, such as ovarian and uterine cancer, and for 
STDs.13 Misunderstandings about the purpose of the Pap test were highly prevalent even 
among women with relevant health experiences, such as those with a history of abnormal 
Pap test results or a previous cervical cancer diagnosis. Only 17.9% of women respondents 
correctly identified the Pap test as being a screen for cervical cancer exclusively.13 These 
results indicate widespread misconceptions about the purpose of Pap testing. Another study 
resulting from the HealthStyles data analysis investigated the knowledge and behaviors of 
women about the cancer antigen-125 (CA-125) blood test and ovarian cancer. This study 
showed that about 25% of women reported having heard of the CA-125, with about 10% of 
women reporting having previously received a CA-125 blood test.24 Characteristics of 
women who had not heard of or had the CA-125 blood test were similar to those who had, 
with the exception that those who had heard of it/had it were more often older and 
perimenopausal or postmenopausal.24 Concern for getting ovarian cancer did not differ 
significantly among women who heard of/had the CA-125 test compared to those who had 
not heard of or had it.24 A third analysis from the same survey data examined self-reported 
intent to seek care for symptoms associated with ovarian cancer. The results showed that 
gynecologic symptoms (such as post-menopausal bleeding) prompted more intention to seek 
care than those that would be considered less gynecologic in nature but are, in fact, 
associated with ovarian cancer (e.g., feeling full after eating a small amount).16 For most 
symptoms, postmenopausal women and those concerned about getting ovarian cancer more 
often responded that they intended to seek care than did younger women and those without 
such concern.16 All these studies and data analyses—several of which are continuing—will 
further help Inside Knowledge campaign planners develop messages and educate women 
about gynecologic cancer symptoms, including those that are nongynecologic in nature.
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DocStyles is an annual survey of physicians who practice in the United States and treat at 
least 10 patients a week and have been in practice for at least 3 years. One thousand primary 
care physicians (510 family/general practitioners and 490 internists) and 250 obstetrician/
gynecologists responded to our DocStyles questions on HPV vaccination, CA-125, 
transvaginal ultrasound, and pelvic examination knowledge and beliefs. Analyses from the 
DocStyles survey indicated that almost 50% of primary care physicians responded that 
CA-125 alone or CA-125 and transvaginal ultrasound were effective ovarian cancer screens 
in the asymptomatic, average-risk population,24 a belief that is inconsistent with screening 
guidelines for ovarian cancer. Obstetrician/gynecologists more often had guidelines-
consistent responses, with a little over half (56%) responding that neither CA-125 nor 
transvaginal ultrasound was an effective screen in the asymptomatic, average-risk 
population, compared to internists and general or family practitioners. The large percentage 
of physicians whose responses were inconsistent with current screening recommendations 
underscores the need for more education about both the current lack of a screening test for 
ovarian cancer and the potential harms of the CA-125 blood test.
Analyses of data from the 2008 and 2009 surveys are ongoing. In 2009, the Inside 
Knowledge campaign commissioned similar questions in the HealthStyles and DocStyles 
surveys, and questions about primary care physician referral patterns to gynecologic 
oncologists for ovarian cancer care also were asked. These questions probe referrals to and 
treatment by gynecologic oncologists, as evidence has shown that such referrals, particularly 
for women with ovarian cancer, result in better survival rates.25 Analyses of these questions 
can potentially reveal barriers to receipt of appropriate care, and suggest further avenues for 
targeted education through the campaign.
Patient and Healthcare Provider Materials Development
Inside Knowledge educational materials are developed in consultation with CDC scientists 
and external gynecologic cancer experts to ensure scientific and medical accuracy. All 
materials undergo multiple rounds of rigorous review for technical content and consumer 
appropriateness. The campaign has developed a robust suite of patient education resources, 
several of which are available in English and Spanish (Fig. 1).
Materials created to date include fact sheets on each of the five main gynecologic cancers, a 
comprehensive gynecologic cancer brochure, print and broadcast PSAs, posters, out-of-
home advertising (such as airport and other transit and shopping mall dioramas), and a 
gynecologic cancer symptoms diary (Fig. 2). All patient education materials are available 
for preview or download from the campaign’s website, www.cdc.gov/cancer/knowledge. 
The campaign’s website itself is revised and updated periodically, with new features and 
resources added as they become available. For example, in March 2011, a new feature, 
Survivor Stories, was added, along with new design elements and photos for the campaign’s 
homepage. The campaign also employs and incorporates novel communication tools, as 
resources allow, to widely disseminate campaign materials. New technologies and social 
media channels used to date include Facebook, Twitter, podcasts, CDC Radio, CDC TV, 
electronic greeting cards, and CDC’s YouTube Streaming Health Channel.
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The patient education materials created by Inside Knowledge are designed to also be useful 
to healthcare providers in their communication with patients about gynecologic cancers. To 
that end, CDC has displayed campaign resources at a variety of healthcare provider 
professional meetings and presented papers and posters at professional gatherings whenever 
possible. Development of additional provider materials will be determined by analysis of 
recently completed provider formative research.
Future materials for healthcare providers likely will emphasize increasing awareness and 
knowledge of gynecologic cancer etiology, appropriate screening and diagnostic tests (e.g., 
the role of the Pap test in cervical cancer screening), genomics and cancer risk, symptom 
recognition, effective communication with patients about gynecologic cancers, and the 
importance of timely referral to gynecologic oncologists for patients diagnosed with 
gynecologic cancers. By developing and making such resources available, CDC hopes to 
increase healthcare provider knowledge of gynecologic cancer issues, which may translate 
to improved care for women.
Public Service Announcements Development and Dissemination
Inside Knowledge PSAs were developed after focus group research with women around the 
country to evaluate message salience as well as creative appeal and clarity. In September 
2010, Inside Knowledge released its first PSAs: four TV PSAs, four radio PSAs, and three 
print PSAs, available in English and Spanish. Several of these include women’s first-person 
accounts of recognizing symptoms, seeking a diagnosis, receiving treatment, and being 
hopeful for a healthy future. The spots urge women to know what is normal for them and 
inform women that:
Warning signs are not the same for everyone. Know what’s normal for you. And if you think 
something’s wrong, see your doctor. Ask about gynecologic cancer. Get the facts. Get the 
Inside Knowledge.
After launching the campaign’s first PSAs in 2010, CDC developed additional TV and print 
PSAs, as well as other out-of-home advertising, and began releasing them in May 2011. The 
latest spots feature writer/performer Jenny Allen, a survivor of both uterine and ovarian 
cancers who wrote and performed a one-woman stage show called, “I Got Sick Then I Got 
Better.” In Inside Knowledge PSAs, she speaks about the importance of recognizing 
symptoms and encourages women who notice anything unusual to: Be brave, go to the 
doctor, ask questions (Fig. 3a).
The Inside Knowledge PSAs have been distributed throughout the United States to more 
than 1,500 English and Spanish network, cable, and local television outlets; 6,200 radio 
outlets; and 2,000 magazines and newspapers. Out-of-home placements (as of June 2011) 
include airport dioramas, posters and similar displays in shopping malls, and bus/bus shelter 
displays. Currently, the campaign relies on donated placements in all media.
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PSA Tracking and Process Evaluation
The campaign uses several methods of tracking: monitoring website hits, publication orders, 
public inquiries, social media and search engine mentions, and PSA use. TV PSA use is 
monitored electronically, with PSAs specially encoded to con-firm when and where they are 
broadcast. Radio PSA use is similarly tracked through a combination of electronic 
monitoring and bounce-back cards from stations. Print ad use is tracked using a national 
media monitoring and clipping service.
Perhaps the most impressive data to date centers on television and radio PSA tracking. 
Process evaluation shows that as of June 2011, Inside Knowledge broadcast PSAs have 
generated more than 465,850,445 audience impressions (the number of times they have been 
seen or heard), worth about $24 million in donated placements. Affiliate stations of all the 
major television networks have aired the spots in 131 markets, including 9 of the top 10 and 
21 of the top 25 media markets. The TV spots are broadcast at all times of day, with the 
majority (70%) airing outside the overnight hours of 1 am through 5 am, and 52% airing 
between 9 am and 10 pm. Meanwhile, the campaign’s radio PSAs have aired in more than 
125 media markets, including all of the top 10, and at least 20 of the top 25 media markets.
Inside Knowledge TV PSAs also have been shown on Public Health Television, a network 
installed in reception areas of federally certified rural health clinics, federally qualified 
health centers, and select critical access hospitals. The network’s aim is to reach patients at 
the point-of-care with targeted, culturally tailored, and linguistically appropriate health 
education, wellness, and lifestyle programming to improve health outcomes and ultimately 
reduce healthcare spending. In May 2011, four Inside Knowledge PSAs were aired on this 
network a total of 43,525 times.
The Inside Knowledge website was launched in August 2009. As of June 2011, it had 
generated more than 22,000 hits, or visits. Meanwhile, interest in campaign materials is very 
high. For example, as of July 2011, over 521,000 English and nearly 161,000 Spanish 
gynecologic cancer fact sheets were ordered from the website. An unknown quantity of 
materials has been downloaded/printed from the website.
Engaging Stakeholders
Many national and local groups have an interest in the Inside Knowledge campaign, with 
involvement of several dating to passage of the legislation that created this initiative. 
Campaign partners include Sheryl Silver, who was instrumental in the creation of Johanna’s 
Law, the legislation authorizing development of the campaign and sister of Johanna Silver 
Gordon (for whom Johanna’s Law was named), the Society of Gynecologic Oncologists, the 
Foundation for Women’s Cancer (FWC, formerly the Gynecologic Cancer Foundation), the 
Allied Support Group of the FWC; the Ovarian Cancer National Alliance; the National 
Cervical Cancer Coalition; Fran Drescher’s Cancer Schmancer, and many other groups.
CDC works to keep these and all interested parties informed about campaign activities, new 
resources, and plans. Key partners are important avenues of dissemination for a national 
campaign, such as Inside Knowledge, and can be critical to its success. To that end, as much 
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as funding allows, CDC provides free campaign materials to national and local 
governmental and nongovernmental partners, including those that are part of the CDC’s 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and National 
Comprehensive Cancer Control Program (NCCCP). By taking advantage of the existing 
infrastructure within CDC-funded state, tribal, and territorial programs (such as the 
NBCCEDP and NCCCP), the Inside Knowledge campaign can disseminate campaign 
materials in a cost-effective and efficient manner.
The campaign works with key partners to ensure widespread dissemination of existing 
campaign materials. To maximize resources and efficiency, Inside Knowledge campaign 
leaders continue to critically examine, develop, and disseminate materials through 
collaborative efforts with CDC’s Office of Women’s Health, HHS’s Office on Women’s 
Health, medical professional societies, healthcare providers, and other partners. In all these 
endeavors, CDC continues to evaluate messaging and materials to ensure they are grounded 
in the latest scientific findings about gynecologic cancer risk, screening, symptoms, and 
treatment.
Future Directions
As funding allows, CDC will increase support for activities that will help to inform future 
implementation of the Inside Knowledge campaign. Evaluation plans include conducting 
additional process and formative research to assess the campaign’s implementation, reach, 
and public health impact. As awareness and educational resources are disseminated, CDC 
intends to conduct research to evaluate the effects of the campaign overall and on women’s 
and healthcare providers’ knowledge, attitudes, and behaviors related to gynecologic 
cancers.
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Inside Knowledge fact sheets in English and Spanish. All patient education materials can be 
viewed, printed, and downloaded from the campaign’s website, www.cdc.gov/cancer/
knowledge. The campaign’s website itself is revised and updated periodically, with new 
features and resources added as they become available.
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Inside Knowledge gynecologic cancer symptoms diary.
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Inside Knowledge print public service announcements. (a) Jenny Allen (top), “Be Brave. 
Ask Questions.” (b) Jennie M. (bottom), “Here’s What Happened”.
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